Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Abstract Background Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and efficacious. Patients with newly diagnose...

Full description

Bibliographic Details
Main Authors: Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta, Michael E. Hahn, Pradip De, Casey Williams, Jessica Guido, Benjamin M. Solomon, Rana R. McKay, Amy Krie, Sarah G. Boles, Jeffrey S. Ross, J. Jack Lee, Brian Leyland-Jones, Scott M. Lippman, Razelle Kurzrock
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Genome Medicine
Subjects:
Precision
Personalized
Genomics
Targeted
Clinical trial
Immunotherapy
Online Access:https://doi.org/10.1186/s13073-021-00969-w

Internet

https://doi.org/10.1186/s13073-021-00969-w

Similar Items